Trials / Completed
CompletedNCT01352884
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label, multi-center, first time in human study of AMP-224 in adult patients with cancer that is not responding to standard therapy. This study will be conducted in two stages consisting of a Dose-Escalation stage and an Expansion Stage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMP-224 | Escalating doses of AMP-224 |
| DRUG | AMP-224 | Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2013-11-01
- Completion
- 2014-01-01
- First posted
- 2011-05-12
- Last updated
- 2016-09-05
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01352884. Inclusion in this directory is not an endorsement.